Seagen SGEN Stock
Seagen Price Chart
Seagen SGEN Financial and Trading Overview
| Seagen stock price | 228.74 USD |
| Previous Close | 196.21 USD |
| Open | 196.4 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 196.29 - 197.56 USD |
| 52 Week Range | 116.08 - 207.17 USD |
| Volume | 767.84K USD |
| Avg. Volume | 1.45M USD |
| Market Cap | 37.04B USD |
| Beta (5Y Monthly) | 0.522887 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 222.64 USD |
SGEN Valuation Measures
| Enterprise Value | 35.4B USD |
| Trailing P/E | N/A |
| Forward P/E | -246.92499 |
| PEG Ratio (5 yr expected) | 0.68 |
| Price/Sales (ttm) | 18.018223 |
| Price/Book (mrq) | 13.585969 |
| Enterprise Value/Revenue | 17.223 |
| Enterprise Value/EBITDA | -59.643 |
Trading Information
Seagen Stock Price History
| Beta (5Y Monthly) | 0.522887 |
| 52-Week Change | 19.39% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 207.17 USD |
| 52 Week Low | 116.08 USD |
| 50-Day Moving Average | 198.93 USD |
| 200-Day Moving Average | 158.81 USD |
SGEN Share Statistics
| Avg. Volume (3 month) | 1.45M USD |
| Avg. Daily Volume (10-Days) | 1.19M USD |
| Shares Outstanding | 187.5M |
| Float | 141.51M |
| Short Ratio | 3.73 |
| % Held by Insiders | 0.90% |
| % Held by Institutions | 91.80% |
| Shares Short | 6.18M |
| Short % of Float | 4.41% |
| Short % of Shares Outstanding | 3.30% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -31.54% |
| Operating Margin (ttm) | -32.32% |
| Gross Margin | 10.64% |
| EBITDA Margin | -28.87% |
Management Effectiveness
| Return on Assets (ttm) | -11.60% |
| Return on Equity (ttm) | -22.67% |
Income Statement
| Revenue (ttm) | 2.06B USD |
| Revenue Per Share (ttm) | 11.08 USD |
| Quarterly Revenue Growth (yoy) | 21.89% |
| Gross Profit (ttm) | 207.99M USD |
| EBITDA | -593609024 USD |
| Net Income Avi to Common (ttm) | -648550976 USD |
| Diluted EPS (ttm) | -3.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.49B USD |
| Total Cash Per Share (mrq) | 7.95 USD |
| Total Debt (mrq) | 104.89M USD |
| Total Debt/Equity (mrq) | 3.85 USD |
| Current Ratio (mrq) | 3.648 |
| Book Value Per Share (mrq) | 14.54 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -486582016 USD |
| Levered Free Cash Flow (ttm) | -297927616 USD |
Profile of Seagen
| Country | United States |
| State | WA |
| City | Bothell |
| Address | 21823 30th Drive SE |
| ZIP | 98021 |
| Phone | 425 527 4000 |
| Website | https://www.seagen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3256 |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Q&A For Seagen Stock
What is a current SGEN stock price?
Seagen SGEN stock price today per share is 228.74 USD.
How to purchase Seagen stock?
You can buy SGEN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Seagen?
The stock symbol or ticker of Seagen is SGEN.
Which industry does the Seagen company belong to?
The Seagen industry is Biotechnology.
How many shares does Seagen have in circulation?
The max supply of Seagen shares is 188.66M.
What is Seagen Price to Earnings Ratio (PE Ratio)?
Seagen PE Ratio is 0.00000000 now.
What was Seagen earnings per share over the trailing 12 months (TTM)?
Seagen EPS is 0 USD over the trailing 12 months.
Which sector does the Seagen company belong to?
The Seagen sector is Healthcare.
Seagen SGEN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16920.58 USD — |
-0.58
|
6.33B USD — | 16873.97 USD — | 16989.6 USD — | — - | 6.33B USD — |
| US100 NDX | 18736.75 USD — |
-0.7
|
740.92M USD — | 18706.63 USD — | 18814.81 USD — | — - | 740.92M USD — |
| Dow Jones U.S. Biotechnology In DJUSBT | 2757.65 USD — |
-1.11
|
86.37M USD — | 2746 USD — | 2775.01 USD — | — - | 86.37M USD — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1379.17 USD — |
-0.81
|
— — | 1374.72 USD — | 1383.25 USD — | — - | — — |
| NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| Nasdaq-100 ESG Net Notional Tot NDXESG24 | 1548.71 EUR 1692.95 USD |
-0.09
|
— — | 1541.97 EUR 1685.58 USD | 1555.23 EUR 1700.08 USD | — - | — — |
| NASDAQ 100 Equal Weighted NDXE | 7334.66 USD — |
-1.08
|
— — | 7331.3 USD — | 7358.65 USD — | — - | — — |
| NASDAQ-100 PM Settlement Value XQC | 16331.98 USD — |
+1.13
|
— — | 16331.98 USD — | 16331.98 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ 100 Notional Net Total R XNDXNNR | 21592.02 USD — |
-0.7
|
— — | 21557.3 USD — | 21681.98 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4633.82 USD — |
-1.19
|
— — | 4606.47 USD — | 4646.26 USD — | — - | — — |
| NASDAQ 100 Pre Market Indicator QMI | 18689.17 USD — |
-0.96
|
— — | 18684.4 USD — | 18781.3 USD — | — - | — — |
| NASDAQ-100 Reduced Value Index NQX | 3747.35 USD — |
-0.7
|
— — | 3741.33 USD — | 3762.96 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8246.62 USD — |
-0.57
|
— — | 8223.97 USD — | 8280.54 USD — | — - | — — |
| NASDAQ 100 Ex Tech Sector NDXX | 5177.64 USD — |
-0.96
|
— — | 5170.65 USD — | 5190.03 USD — | — - | — — |
| Nasdaq-100 ESG JPY Index NDXESG07 | 1985.02 JPY 13.4 USD |
-0.23
|
— — | 1977.67 JPY 13.35 USD | 1994.92 JPY 13.47 USD | — - | — — |
| Stlmt ID NASDAQ 100 XQO | 16266.86 USD — |
-0.45
|
— — | 15738.2 USD — | 16639.8 USD — | — - | — — |
| Nasdaq-100 Notional Net Return XNDXNNREUR | 3586.12 EUR 3920.12 USD |
-0.15
|
— — | 3573.16 EUR 3905.95 USD | 3600.94 EUR 3936.31 USD | — - | — — |
| NASDAQ Biotechnology NBI | 4311.81 USD — |
-1.19
|
— — | 4286.36 USD — | 4323.39 USD — | — - | — — |
| Nasdaq-100 Micro Index XND | 187.37 USD — |
-0.7
|
— — | 187.07 USD — | 188.15 USD — | — - | — — |
- {{ link.label }} {{link}}